CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial

Abstract Background There have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients. Methods Patients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed. Results Three hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718–7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789–11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054–13.369; P = .041) in the anti-HBc positive cases. Conclusions Higher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

Download Full-text

Telomere Length as a Prognostic Factor for Overall Survival in Colorectal Cancer Patients

Cellular Physiology and Biochemistry ◽

10.1159/000438614 ◽

2016 ◽

Vol 38 (1) ◽

pp. 122-128 ◽

Cited By ~ 14

Author(s):

Houjun Jia ◽

Ziwei Wang

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Prognostic Factor ◽

Telomere Length ◽

Cancer Patients ◽

Random Effects ◽

Fixed Effects ◽

Systemic Review ◽

Colorectal Cancer Patients ◽

Cancer Tissues

Background/Aims: The stabilization of telomere length has important roles in the carcinogenesis of colorectal cancer. A systemic review and meta-analysis of published studies was performed to assess the prognostic role of telomere length in colorectal cancer. Methods: Pubmed and Embase were searched for eligible studies on the association between telomere length and overall survival in colorectal cancer patients. The pooled hazard ratio (HR) and corresponding 95% confidence intervals (95%CI) was calculated using fixed-effects or random-effects model according to the magnitude of between-study heterogeneity. Results: Seven individual studies with a total of 956 colorectal cancer patients were included. Long telomere length in cancer tissues was marginally associated with poorer overall survival (Random-effects HR = 1.85, 95% 0.90 to 3.83, P = 0.09). When using studies with adjusted estimates, long telomere length in cancer tissues was independently and significantly associated with poorer overall survival (Fixed-effects HR = 2.70, 95% 1.51 to 4.84, P = 0.001). However, short telomere length in peripheral blood leukocytes was independently and significantly associated with poorer overall survival (Fixed-effects HR = 2.01, 95% 1.46 to 2.77, P < 0.001). Conclusions: There is some evidence for telomere length as a prognostic factor for overall survival in colorectal cancer patients. More studies with large number of participants are needed to further assess the prognostic significance of telomere length in colorectal cancer patients.

Download Full-text

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.3512 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 14

Author(s):

Marc Ychou ◽

Michel Rivoire ◽

Simon Thezenas ◽

Rosine Guimbaud ◽

Francois Ghiringhelli ◽

...

Keyword(s):

Colorectal Cancer ◽

Targeted Therapy ◽

Liver Metastases ◽

Cancer Patients ◽

Phase Ii ◽

Randomized Study ◽

Ras Status ◽

Colorectal Cancer Patients

Download Full-text

Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2019.1642324 ◽

2019 ◽

Vol 20 (14) ◽

pp. 1767-1775 ◽

Cited By ~ 1

Author(s):

Anas M Saad ◽

Omar Abdel-Rahman

Keyword(s):

Colorectal Cancer ◽

Targeted Therapy ◽

Liver Metastases ◽

Cancer Patients ◽

Colorectal Cancer Patients ◽

Therapy Strategies

Download Full-text

Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases

Tumor Biology ◽

10.1177/1010428317752944 ◽

2018 ◽

Vol 40 (1) ◽

pp. 101042831775294 ◽

Cited By ~ 7

Author(s):

Reetta Peltonen ◽

Pia Österlund ◽

Marko Lempinen ◽

Arno Nordin ◽

Ulf-Håkan Stenman ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Liver Resection ◽

Liver Metastases ◽

Cancer Patients ◽

Prognostic Marker ◽

Colorectal Liver Metastases ◽

Prognostic Significance ◽

University Hospital ◽

Colorectal Cancer Patients

Liver metastases of colorectal cancer can be operated with a curative intent in selected cases. However, more than half of the patients have a recurrence. The aim of this study was to evaluate the prognostic and predictive value of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), human chorionic gonadotropin β (hCGβ) and tumour-associated trypsin-inhibitor (TATI) in colorectal cancer patients before and 3 months after resection of liver metastases. Marker concentrations were determined in blood samples from 168 colorectal cancer patients, who underwent liver resection between the years 1998 and 2007 at Helsinki University Hospital, Finland. The samples were taken before and 3 months after curative resection. Increased concentrations of CEA (>5 µg/L) and hCGβ (>1 pmol/L) 3 months after liver resection correlated with recurrence and impaired overall survival and increased CA19-9 (>26 kU/L) with impaired overall survival, but postoperative TATI was not prognostic. Preoperatively elevated CEA and CA19-9 correlated with impaired overall survival, but not with recurrence. Neither preoperative hCGβ nor TATI was prognostic. In conclusion, CEA is a useful prognostic marker, when measured 3 months after resection of colorectal liver metastases. CA19-9 also has prognostic significance and may have additional value.

Download Full-text